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gives support for the practical use of the preparations in 
human medicine. Mistletoe lectins (ML) I, II and III (com-
plex proteins of high molecular weight 30–120kDa) are 
believed to be the active component of mistletoe extracts, 
since they achieve a prominent cytotoxic effect in low con-
centrations and are consequently the best investigated 
components of mistletoe extracts17,18. Still, lectins are not 
the only active substances in aqueous mistletoe extracts19. 
Biologically active substances, such as viscotoxins, fl avo-
noids, oligosaccharides, alkaloids, lipids, phytosterols, 
triterpens, and several enzymes are also present causing 
the increase in overall activity of the extract compared to 
the pure lectins17,18. Nowadays, viscotoxins are cloned in 
Escherichia coli making them accessible for possible ap-
plication in cancer therapy20.
Introduction
Mistletoe (Viscum album) has a long history as plant 
source for the preparation of different extracts used for 
therapy of cancer1–7. Namely, numerous data point to a 
cytotoxic action of these extracts against different tumor 
cell lines, while their in vitro toxicity for the normal, or at 
least less malignant, cells is less pronounced, indicating 
relatively selective toxicity primarily against the tumor 
cells8–14. On the other hand, the application of the Viscum 
album extracts in vivo might have immunomodulating ef-
fects, mainly stimulating cytotoxic activity of lympho-
cytes12,13,15,16. The dual activity of the mistletoe prepara-
tions, i.e. cytotoxicity for the tumor cells and enhancement 
of the immune host defense against the malignant cells, 
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A B S T R A C T
Within the integrative medicine one of the most frequently used adjuvant cancer biotherapies is based on aqueous 
mistletoe (Viscum album) extracts. Tumor growth inhibition, stimulation of host immune response and improvement of 
the quality of life are the positive effects of mistletoe therapy described in several preclinical and clinical studies. How-
ever, cumulative results of the evidence based medicine fi ndings on such treatments are rarely given. Therefore, this paper 
evaluates the evidence based fi ndings describing effects of the Viscum album extract Isorel in cancer therapy with respect 
to the type of therapy, stage and type of illness. This study presents cumulated data for 74 patients with different types 
and stages of cancer treated by Viscum album extract as adjuvant treatment to different conventional therapies, mostly 
combined surgery and radiotherapy. The biotherapy effectiveness was evaluated according to the outcome as 1) no major 
therapeutic improvement (15% of patients), 2) prevention of tumor recurrence (47% of patients) and 3) regression of cancer 
(38% of patients). Notably, there was no obvious health worsening during the follow up period at all. Thus, the results 
obtained for conventional anticancer therapies combined with adjuvant biotherapy based on Viscum album extract seem 
to be benefi cial for the majority of cancer patients (85%) without serious side effects.
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Initial clinical trials were promising, therefore, cur-
rently prospectively randomized multicentre trials are 
being performed to evaluate the ability of complementary 
ML–1 treatment to reduce the rate of tumor recurrences 
and metastases, to improve the overall survival as well as 
the quality of life and to exert immunoprotection in cancer 
patients under tumor destructive therapies21–23. These 
fi ndings are in agreement with previous clinical studies 
that indicated usefulness of various Viscum album ex-
tracts in the therapy of cancer24. However, in such studies 
it is often diffi cult to compare results obtained using dif-
ferent types of plant extracts for therapy of different types 
of cancer at different stages of illness. We have described 
previously that a tetrazolium salt based colorimetric assay 
(MTT) is applicable as in vitro assay for the analysis of the 
batch consistency of one of registered Viscum album aque-
ous extracts, namely the  drug Isorel25 (Vysorel®). Hence, 
it was found that the biological activity of the drug could 
be considered as standardized if compared to the activity 
of the purifi ed ML–1. Taken together, the anticancer effect 
of the extract was proven in various in vitro and in vivo 
experimental models11,13 with clinical trials showing its 
benefi cial effects in the therapy of cancer patients21,22. The 
aim of this study was to summarize evidence based fi nd-
ings on Isorel anticancer activity using the current ap-
proach of evidence based medicine (EBM) in discussion of 
the fi ndings26.   
Materials and Methods
Viscum album extract
A preparation of the fresh plant aqueous extract (Novi-
pharm GmbH, Austria) was used s.c., i.m. and i.v. accord-
ing to the recommended, registered producer’s protocols 
and physicians’ expertise of their patients. The Viscum 
album extract Isorel is produced under GMP standards by 
cold extraction of the entire plant in saline, without homog-
enization of the plant or extract fermentation. It contains 
several active substances: mistletoe lectines, viscotoxines, 
fl avonoides, polysaccharides, triterpenes, etc. However, it 
should be mentioned that the plain drug is a more effective 
tumoricidal agent than any of its active components alone 
showing adjuvant therapeutic effi cacy of the bioactive mis-
tletoe components27. Moreover, the overall anticancer ef-
fects of the drug show very good batch consistency, as 
verifi ed by standardised bioassay on several cell lines, and 
resemble anticancer effects of the purifi ed mistletoe lec-
tines (ML–1)25.
On the other hand, relative proportions of the plant 
extract components differ not only regarding to the mistle-
toe host–trees and seasonal variations of different years, 
but also regarding the respective time of harvest. There-
fore, quantitative specifi cations can be made only in a wide 
concentration range for each substance, while the fl avo-
noids are the lead substance from point of view of quality 
control. According to the European Pharmacopoeia 
(2.2.27) a validated qualitative identifi cation of the differ-
ent Isorel–preparations (A, M, P) is possible through dis-
tinct fi ngerprints obtained by thin layer chromatography 
(TLC). Namely, Isorel and a reference solution of fl avo-
noids are applied on a stationary phase (silica gel on alu-
minum foil) and are together with the mobile phase (a mix-
ture of ethyl acetate, ethylmethylketone, formic acid and 
water) drawn up the silica gel plate via capillary action. 
Consequently separation of fl avonoids is achieved, because 
of their different mobility in TLC (Fig. 1, courtesy of Novi-
pharm GmbH).
Thus, the GMP produced and by bioassay validated, ac-
cording to the fl avonoid content standardised types of Isorel 
prepared from the fi r tree mistletoe – Abies (A), apple tree 
– Mali (M) and pine tree – Pini (P) were used. Selection of 
the type of drug applied depending on the type of the host 
tree is based on the practical experience of medical doctors 
obtained over decades of practical work, as in case of other 
mistletoe drugs. They all followed manufacturer’s recom-
mendations and complied with them. Upon request the 
Isorel manufacturer (www.novipharm.at/english/home.
html) provides any other needed information both to the 
medical practitioners as well as to the patients. All pa-
tients were receiving Isorel according to the guidelines for 
this complementary biotherapy. Therefore, they were 
treated every second day for three times a week during 
the fi rst year after cancer diagnosis, while in case of can-
Fig. 1. TLC-fi ngerprint of Isorel® (=Vysorel®) 
A, M and P Strength 60 The thin-layer chromatography 
analyses based on Pharm. Eur., monograph Birch Leaf (7.0/1174) 
conforms to respective authentic reference sample revealing the 
content of fl avonoids in Isorel as A: 16-35 μg/ml, M: 5-18 μg/ml 
and P: 28-65 μg/ml respectively.
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cer remission the treatment was after fi rst year reduced 
to one per week and was maintained in such a way after-
wards. In case of chemotherapy or radiotherapy, Isorel was 
used between the cycles of these treatments, while in case 
of surgery Isorel was introduced from convalescence fur-
ther. The patients did not have to pay for Isorel therapy, 
since it was covered by the health insurance funds.
Patients
Documentation in form of brief case reports was ob-
tained for 45 patients provided by the drug producer No-
vipharm, while the other 29 cases were evaluated on the 
basis of the published case reports. Thus, in total there 
were 74 case reports analysed for 46 female and 28 male 
patients aged from 26–88 years (average 57) monitored 
for different time intervals (4 to 156 months, on average 
31,8) as shown in Table 1. The overall duration of the 
therapy with Isorel was individually determined, since the 
monitoring period was also different for different patients, 
as reported by their doctors who provided the evidence 
base data analysed. All the patients were using Isorel con-
tinuously following the guidelines of the pharmaceutical 
company Novipharm relaying also on the positive experi-
ence of the doctors. The documentation received could be 
considered as case reports in which staging of the malig-
nant disease was done in respective clinics where patients 
were diagnosed and treated initially (by surgery, chemo– 
and radio–therapy) that relied on the TNM classifi cation. 
There were no particular additional diseases noticed 
which could be considered of major relevance for the effi -
ciency of the therapy during the time studied (except pneu-
monia in one case and diabetes in the other, but in both 
cases of uncertain relevance for the therapy applied).
Distribution of patients according to type of cancer
Patients included in the study were suffering form dif-
ferent types of cancer localized in almost all organic sys-
tems (Fig. 2). Mostly they had mammary carcinoma 
(N=21) or carcinoma developed in the digestive system 
(N=21) in almost each possible location (in particular co-
lon and rectum).
Patients were initially divided into three groups (Fig. 
3). The fi rst group denoted as “initial” (N=25) were pa-
tients with tumors in an early stage of development, with 
the assumption the cancer did not have any manifested 
metastases. The second and third groups were denoted 
Fig.2. Classifi cation of patients by cancer localization/type.  Mammary carcinoma and digestive tract carcinoma 
were the most common.
Fig. 3. Classifi cation of patients by the stage of tumor develop-
ment.  Patients were distributed in 3 groups denoted as initial 
– without metastases; advanced – with local metastases; 
advanced – with remote metastases in other organs.
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“advanced” with difference in severity, namely, second 
group (N=34) consisted of patients with advanced cancer 
without or with only local metastases, unlike the third 
group (N=15) which had remote metastases in other or-
gans.
Distribution of patients according to therapy 
applied
As can be seen from Fig. 4, there were only 12 patients 
who were treated by Isorel solely (one patient received ini-
tially for one week another Viscum album, extract – Isca-
dor®, which was replaced by Isorel afterwards for six 
years), while the other patients received Isorel after or in 
parallel to the applied therapeutic protocols. Most of the 
patients (N=36) received Isorel combined with radiothera-
py and/or chemotherapy, which were applied for 27 patients 
after surgery, while 9 patients were not surgically treated. 
There were 26 patients treated with Isorel after surgery 
(removal of cancer and, desirably, some local lymph nodes) 
who did not receive radiotherapy or chemotherapy. One 
patient was for the initial period of one week receiving 
another type of the mistletoe extract, which was replaced 
by Isorel afterwards for the consecutive period of six years. 
Statistics
The results obtained were evaluated using Chi–square 
test to defi ne distribution of the patients according to the 
outcome in dependence on the type of cancer, stage of dis-
ease and therapies applied.    
Results
Therapeutic effi ciency – general fi ndings
Most of the patients (35/74 – 47%) did not have signs of 
tumor recurrence and/or metastases developed, at least 
during the time monitored (Figure 5). The incidence of 
these patients in comparison to those that showed no ma-
jor improvement (N=11, 15%) or oppositely signs of tumor 
regression (N=28, 38%) was signifi cantly (p=0.0006) 
higher. There were no patients at all with signs of severe 
worsening of the health due to the cancer progression. 
Thus, from this study it could be concluded that the major 
therapeutic effects of Isorel therapy alone or combined 
with conventional therapy is prevention of the tumor re-
currence and/or prevention of development of metastases.
Therapeutic effi ciency – dependence on the stage of 
illness
The stage of illness did not strongly infl uence the effi -
ciency of the therapies applied (see Table 2). For the pa-
Fig. 4. Classifi cation of patients by therapy received. Only 12 
patients received solely Isorel, 26 were treated with Isorel after 
surgery and 36 were treated with Isorel in combination with 
surgery and/or radiotherapy with or without chemotherapy.
TABLE 1
DISTRIBUTION OF PATIENTS ACCORDING TO THE AGE, SEX 
AND TIME MONITORED
Male Female Total
Number of patients 28 46 74
Age range 26–88 33–85 26–88
Mean 58.17 56.30 57.22
Follow up (month)
Male Female Total
Range 4–144 6–156 4–156
X 33.14 30.86 31.79
Fig. 5. The effects of Isorel therapy. The majority of patients 
(47%) did not exhibit have tumor recurrence in the follow up 
period, 38% of patients showed had incomplete regression, and 
15% did not have any improvement. There were no patients 
with severe worsening of the health due to cancer progression.
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tients with initial phase of cancer the most common fi nd-
ing of the outcome was prevention of the tumor recurrence 
and/or prevention of development of metastases (p<0.0001). 
The group of patients with advanced cancer mostly associ-
ated with regional metastases (N=34), did not show the 
same results. Namely, there was no prevalence of a par-
ticular outcome in these patients (p=0.138). However, if 
patients with the most favorable outcome (partial or com-
plete regression of primary tumor and/or metastases) were 
combined with the group of patients whose outcome was 
defi ned as “prevention of development of metastases and/
or cancer recurrence”, the total incidence of these patients 
was 82%, versus 18% that showed only improved general 
health condition (p=0.0002). Further, patients suffering 
from the most advanced cancer associated with remote 
metastases (N=15) did not have any principal anticancer 
effects of applied therapy (p=0.0743). Namely, only in 13% 
patients the therapies applied showed effects of prevention 
of the tumor recurrence and/or prevention of metastases 
development, while in 27% patients no major improvement 
was observed (except improved general quality of life, such 
as appetite, activity, etc.). In the group of patients with the 
most advanced illness there were also 60% patients who 
showed favorable results of the therapy that could be de-
fi ned as regression of the primary tumor as well as preven-
tion of the tumor recurrence or metastases, at least during 
the period monitored. In spite of that, combining the two 
benefi cial outcomes (prevention of tumor recurrence and 
(in)complete regression of tumor and/or metastases; N=11) 
and comparing it to those with only palliative improve-
ment of general well being (N=4)  did not give a signifi cant 
difference (p=0.0703) for patients with the most advanced 
cancer.
Dependence of the outcome on the type of therapy
As can be seen from Table 3, the most common outcome 
(p=0.0006) was prevention of tumor recurrence and/or 
prevention of metastases development (N=36) which was 
the signifi cantly dominant outcome in patients treated 
with combined therapies (p=0.0488) and for patients re-
ceiving Isorel after surgery (p=0.0001). Such a distribu-
tion was not noticed for patients receiving Isorel solely, 
since there was only one patient in this group with such 
outcome. Therefore, the highest incidence was in the group 
of patients showing signs of tumor regression (p=0.0087). 
A positive impact of radiotherapy and chemotherapy 
was noticed in comparison to the patients with therapy 
consisting only of surgery and Isorel. Namely, if the pa-
tients receiving combined therapies (N=36) were com-
pared with those receiving only surgery and Isorel (N=26), 
the incidence of the outcome defi ned as “prevention of tu-
mor recurrence or metastases”, signifi cantly decreased 
(from 73% to 44%) in favor of the most desired effects de-
fi ned as “regression of the tumor and prevention of tumor 
recurrence or metastases” that increased from 15% to 42% 
(p=0.0097).
TABLE 2
THE EFFECTS OF CANCER THERAPIES APPLIED ACCORDING TO THE STAGE OF ILLNESS
OUTCOME (during the period monitored [4 to 156 months])
Stage of  illness No major therapeutic 
improvement
Prevention of metastases 
and/or recurrence
(In)complete regression of primary tumor + 
prevention of metastases and/or recurrence
Total
Initial – no metastases 1 20 4 25
Advanced – regional metastases 6 13 15 34
Advanced – remote metastases 4 2 9 15
Total 11 35 28 74
TABLE 3
THE EFFECTS OF CANCER THERAPIES APPLIED ACCORDING TO THE TYPE OF THERAPY USED
OUTCOME (during the period monitored [4 to 156 months])
type of therapy No major therapeutic 
improvement
Prevention of metastases 
and/or recurrence
(In)complete regression of primary tumor + 
prevention of metastases and/or recurrence
Total
Isorel only 2 1 9 12
Isorel + surgery 4 18 4 26
Combined = Isorel + surg.+ 
radioth.+ chemoth.
5 16 15 36
Total 11 35 28 74
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Dependence of the effects of therapies on the type of 
cancer
Because the outcome of different cancers is often dif-
ferent due to their sensitivity to similar kinds of therapy, 
for the evaluation of the data available, the patients were 
further separated into three major subgroups denoted as: 
1) patients with mammary carcinoma (N=21); 2) patients 
with gut cancer (colon or rectum carcinoma) (N=11) and 
3) patients with other types of cancer (including lympho-
ma/leukemia, carcinoma of pancreas and gall bladder, 
bronchial and thyroid cancer, various malignancies of 
CNS, as well as Schwanoma, liposarcoma, prostatic can-
cer, ovarian carcinomas, in total N=42). The fi ndings of 
the infl uence of type of cancer on the outcome are pre-
sented in Table 4.
For all three groups of patients benefi cial effects of 
therapies (combined “prevention of tumor recurrence and/
or metastases development” and “(in)complete regression 
of cancer”) were much more pronounced compared to im-
proved quality of life only, denoted as “no major therapeu-
tic improvement” (for all the groups and total, p<0.01). 
While for patients with colon cancer the major benefi cial 
outcome was prevention of tumor recurrence (82%) due to 
the early cancer diagnosis and therapy applied at the ini-
tial stage (see Table 1), for the other two subgroups (mam-
mary carcinoma versus all other types of cancer) the same 
distribution of the effectiveness of therapies was observed 
(p=0.2381). For these two subgroups “prevention of tumor 
recurrence or metastases development” gave the same in-
cidence as “(in)complete regression” (for mammary carci-
noma, p=0.4913; for other cancers, p=0.3778) thus indicat-
ing that the type of cancer was not as relevant a 
parameter for the determination of effects of therapies ap-
plied as was the stage of illness. 
Discussion
Aqueous mistletoe extracts are used by a large number 
of cancer patients, and more and more studies confi rm its 
benefi cial effects on various type of cancer14,21,28. Evidence 
gained over the last two decades has classifi ed the mistle-
toe extract therapy as one of the most attractive approach-
es in adjuvant cancer therapy, as acknowledged by the 
National Institute of Health, although these drugs are not 
yet registered by the Food and Drug Administration in the 
USA (www.cancer.gov/cancertopics/pdq/cam/mistletoe/
HealthProfessional). Still, there are some inconsistent 
conclusions from some clinical trials, mainly due to differ-
ent types of drugs and protocols used24,29.
Mistletoe extracts showed dual activity in tumor pa-
tients, exerting cytotoxicity against tumor cell on the one 
hand and immunomodulating effects on the other. Various 
authors report selective cytotoxicity against different tu-
mor cell lines, with no pronounced toxicity against non 
malignant cell lines13,30,31. Immunomodulating effects of 
mistletoe extracts are of value in cancer therapy because 
combined immuno depressive effects of cancer and surgery 
may augment the risk of postoperative infections and dis-
semination of malignancy, leading to the reduction of over-
all recovery and quality of life. Most of the studies showed 
benefi cial effects of different mistletoe extracts in patients 
with certain cancer types14,21 but there are not enough cor-
relation data of the mistletoe therapy and its outcome in 
tumor patients grouped on different bases. Therefore, here 
we evaluate the therapeutic effect of the mistletoe extract 
Isorel on several different bases: stage of illness, type of 
therapy and type of illness. 
For the evaluation of the effects of mistletoe extracts 
we have used the drug Isorel, a total aqueous extract of 
mistletoe. Previous studies endorsed Isorel as immuno-
modulating agent with cytotoxic effect toward malignant 
cells thereby increasing the effi ciency of radio– and che-
motherapy3,6. Most studies showed a perspective in com-
bined chemotherapy and Isorel biotherapy6,25,32. Our study 
showed that biotherapy with Isorel had positive effects, 
with the most common outcome favorable for patients 
causing prevention of tumor recurrence and prevention of 
metastases. Encouragingly, there was no severe worsen-
ing of health due to cancer progression. Especially effec-
tive was the combination of radio– and/or chemotherapy 
with or without surgery and Isorel biotherapy. Namely, the 
combination of therapies gave two favorable outcomes in-
dicating the importance of adjuvant therapy in treating 
the cancer.
The stage if illness is especially important in cancer 
treatment as early detection of tumor increases the chanc-
es of recovery. Indeed, if Isorel is used as adjuvant therapy 
TABLE 4
THE EFFECTS OF CANCER THERAPIES APPLIED ACCORDING TO THE TYPE CANCER
OUTCOME (during the period monitored [4 to 156 months])
Type of cancer No major therapeutic 
improvement
Prevention of metastases 
and/or recurrence
(In)complete regression of primary tumor + 
prevention of metastases and/or recurrence
Total
Mammary carcinoma 2 11 8 21
Colon + rectum carcinoma 1 9 1 11
Other 8 15 19 42
Total 11 35 28 74
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in an initial stage of the illness the chances for a positive 
outcome of the therapy are high. The progression of the 
illness shift this result to (in)complete regression of pri-
mary tumor and prevention of metastases, with no statis-
tical difference between positive outcome and “no improve-
ment” outcome in an advanced stage of illness with remote 
metastases.
One of the problems in cancer treatment is the different 
sensitivity of different cancer types to the same therapy 
which additionally complicates the recovery. Therefore, we 
have analyzed the dependence of Isorel biotherapy on can-
cer type. Interestingly, in all cancer types Isorel biother-
apy showed to be benefi cial for the patient, with the best 
outcome in the group of patients with colon cancer. Many 
studies on mistletoe extract were done on different cancer 
types with an overall conclusion of benefi ts of mistletoe 
therapy11,21,33,34. Also, the majority of studies report the 
infl uence of mistletoe extracts in the advanced stage of the 
illness hence targeting the most critical group of pa-
tients21,33,34. Yet, our analysis showed that benefi cial ef-
fects were not related to cancer type, but rather due to 
early cancer diagnostics and therapy applied in initial 
stage of the illness thereby verifying our previous fi nding. 
These fi ndings might indicate also that due to the rela-
tively high contents of fl avonoids, the mistletoe extract 
Isorel might be effi cient modulator of oxidative homeosta-
sis disturbed in cancer patients thus acting indeed comple-
mentary to the conventional therapies as was suggested 
already, in particular if future studies would reveal inter-
ference of its biotherapeutic effects with the biomodulating 
effects of the oxidative stress mediators, such as 4-hy-
droxynonenal, as was recently observed in vitro for sev-
eral synthetic antioxidants32, 35–37.
Finally, it should be said that the mistletoe extracts 
are in use for cancer therapy for more than 70 years, usu-
ally as adjuvant therapy, as is also the case of Isorel. The 
most prominent effect of Isorel therapy was observed in 
dependence of the stage of the illness. Moreover, the im-
provement in the quality of life and the psycho–emotional 
status with reduction of side effects of chemo/radiotherapy 
made these extracts popular among cancer patients as 
adjuvant therapy. All these fi ndings indicate the relevance 
of adjuvant therapy in cancer treatment not only as anti–
tumor agents which increase the effectiveness of conven-
tional therapy but also as factors of improvement of the 
quality of life.
Acknowledgements
Dedicated to Mrs. Weiss, brave fi ghter and faithful 
friend, gentle lady who joined her husband to be remem-
bered as pioneers of the human magic of mistletoe.
R E F E R E N C E S
1. BÜSSING A, Anti–CancerDrugs, 8 (1997) 1. — 2. STEINER R, 
Spiritual sciences and medicine  (Rudolf Steiner Publishing Co., London, 
1920). — 3. KANNER L, Bulletin of the History of Medicine, 7 (1939) 
875. — 4. KHWAJA TA, DIAS CB, PENTECOST S, PAPOIAN H, Pro-
ceedings of the American Association for Cancer Research 22 (1981) 153. 
— 5. FRANZ H, Oncology, 43 (1986) 1. — 6. KISSEL D, JURIN M, ZAR-
KOVIC N, Deutsche Zeitschrift für Onkologie, 22 (1990) 134. — 7. KLEI-
JNEN J, KNIPSCHILD P, Phytomedicine, 1 (1994) 255. — 8. KLAM-
ERTH O, VESTER F, KELLNER G, Hoppe–seyler’s Z. physio Chem,  349 
(1968) 863. — 9. JUNG ML, BAUDINO S, RIBEREAU-GAYON G, BECK 
JP, Cancer Lett, 51 (1990) 103. — 10. SAMUELSSON G, Syst Zool, 22 
(1974) 566. — 11. HULSEN H, MECHELKE F; Naturwiss, 74 (1987) 144. 
— 12. KISSEL D, JURIN M, ZARKOVIC N, Erfahrungsheilkunde Acta 
Medica Empirica, 39 (1990) 59. — 13. JURIN M, ZARKOVIC N, HRZEN-
JAK M, ILIC Z, Oncology, 50 (1993) 393. — 14. KIENLE GS, GLOCK-
MANN A, SCHINK M, KIENE H, J Exp Clin Cancer Res, 28 (2009) 79. 
— 15. BUSSING A, TRÖGER W, STUMPF C, SCHIETZEL M, Antican-
cer Res, 28 (2008) 1893. — 16. LEE JY, KIM JY, LEE YG, BYEON SE, 
KIM BH, RHEE MH, LEE A, KWON M, HONG S, CHO JY, Biol Pharm 
Bull, 30 (2007) 2043. — 17. GANGULY C, DAS S, Chemotherapy, 40 
(1994) 272. — 18. HEINY BM, BEUTH J, Anticancer Res, 14 (1994) 1339. 
— 19. EGGENSCHWILER J, VON BALTHAZAR L, STRITT B, 
PRUNTSCH D, RAMOS M, URECH K, RIST L, SIMÕES-WÜST AP, 
VIVIANI A, BMC Complement Altern Med, 7 (2007) 14. — 20. BOGO-
MOLOVAS J, SIMON B, SATTLER M, STIER G, Protein Expr Purif, 64 
(2009) 16. — 21. CAZACU M, ONIU T, LUNGOCI C, MIHAILOV A, 
CIPAK A, KLINGER R, WEISS T. ZARKOVIC N, Cancer Biother Ra-
diopharm, 18 (2003) 27. — 22. ENESEL MB, ACALOVSCHI I, GROSU 
V, SBARCEA A, RUSU C, DOBRE A, WEISS T, ZARKOVIC N, Antican-
cer Res, 25 (2005) 4583. — 23. KIENLE GS, KIENE H, Eur J Med Res, 
12 (2007) 103. — 24. KIENLE GS, BERRINO F, BUSSING A, Eur J Med 
Res, 8 (2003) 109. — 25. ZARKOVIC N, KALISNIK T, LONCARIC I, 
BOROVIĆ S, MANG S, KISSEL D, KONITZER M, JURIN M, GRAINZA 
S, Cancer Biother Radiopharm, 13 (1998) 121. — 26. SACKETT DL, 
STRAUS SE, RICHARDSON WS, Evidence based medicine: how to prac-
tice and teach EBM, 2nd ed.(Churchill Livingstone, Toronto, 2000). — 27. 
ZARKOVIC N, JURIN M, DITTRICH W, HARTLEB M, SLADOL JEV 
S, KISSEL D, Comparison of the antitumorous effects of Viscum al bum 
lectins and the plain or fractional fresh plant preparation Isorel. In: Grun-
dlagen der Misteltherapie, (Hippocrates Verlag, Stuttgart, 1996): 325 
— 28.  SCHOFFSKI P, RIGGERT S, FUMOLEAU P, Ann Oncol, 15 
(2004) 1816. — 29. KLEEBERG UR, SUCIU S, BROCKER EB, EJC, 40 
(2004) 390. — 30. HARMSMA M, UMMELEN M, DIGNEF W, Arz-
neimittel-Forschung/Drug Research, 56 (2006) 474. — 31. ZARKOVIC 
N, TRBOJEVIC – CEPE M, ILIC Z, HRZENJAK M, GRANICA S, 
JURIN M, Periodicum Biologorum, 97 (1995) 61. — 32. BUSSING A, 
JURIN M, ZARKOVIC N, AZHARI T, SCHWEIZERET K, Forsch Kom-
plementärmed, 3 (1997) 244. — 33. HAGER ED, MIGEOD F, KOOMAGI 
R, SCHRITTWIESER G, KRAUTGARTNER I, Deutsche Zeitschrift fur 
Onkologie, 41 (2009) 16. — 34. GROSSARTH-MATICEK R, ZIEGLER 
R, Arzneimittel–Forschung/Drug Research, 57 (2007) 665. — 35. CHER-
KAS A, YELISYEYEVA O, SEMEN K,  ZARKOVIC K, KAMINSKYY 
D, CIPAK A, JAGANJAC M,  LUTSYK A, WAEG G, ZARKOVIC N, 
(2009) Coll Antropologicum, 33:315. — 36. LOVAKOVIC T, POLJAK–
BLAZI M, DUBURS G, CIPAK A, CINDRIC M, VIGANTE B, BISE-
NIEKS E, JAGANJAC M,  MRAKOVCIC L,  DEDIC A, ZARKOVIC N 
(2011) Growth Modulation of Human Cells in vitro by Mild Oxidative 
Stress and 1,4–Dihydropyridine Derivative Antioxidants. Coll Antropo-
logicum, 35: 137. — 37. CIPAK GASPAROVIĆ A, LOVAKOVIC T,  ZAR-
KOVIC N (2010) Periodicum Biologorum, 112:433.
708
S. Borovic Sunjic et al.: Cancer Biotherapy using Viscum Album Extract, Coll. Antropol. 39 (2015) 3: 701–708
N. Zarkovic
Rudjer Boskovic Institute, Division of Molecular Medicine, Laboratory for Oxidative Stress, Bijenicka 54, 
HR–10002 Zagreb, Croatia
e–mail: zarkovic@irb.hr
ADJUVANTNA ONKOLOŠKA BIOTERAPIJA VISCUM ALBUM EKSTRAKTOM ISOREL: PRIKAZ 
NALAZA TEMELJENIH NA MEDICINSKIM OPAŽANJIMA
S A Ž E T A K
U okviru integrativne medicine jedan od najčešće korištenih oblika adjuvantne onkološke bioterapije se temelji na 
vodenim ekstraktima imele (Viscum album). U nizu pretkliničkih i kliničkih istraživanja opisani su pozitivni učinci 
terapije ekstraktima imele koji uključuju inhibiciju rasta tumora uz poticanje imunološkog sustava obrane oboljelih i 
poboljšanje kvalitete života. Međutim, sažimanje rezultata podataka dobivenih medicinskim opažanjima za različite 
oblike ovakvih tretmana u osoba oboljelih od različitih oblika tumora se rijetko opisuje. Stoga ovim radom analiziramo 
medicinska opažanja dobivena za bolesnike liječene ekstraktom Isorel ovisno o oblicima sveukupne onkološke terapije, 
stadiju bolesti i tipu zloćudnog tumora. Studija uključuje kumulativne podatke dobivene za 74 bolesnika s različitim 
oblicima malignoma, različitih stadija bolesti koji su uz Isorel primali različite oblike konvencionalne onkološke tera-
pije, pretežito kombinaciju kirurškog zahvata i radioterapije. Uspješnost adjuvantne bioterapije je evaluirana prema 
ishodu kao 1) bez znatnijih terapijskih učinaka (15% bolesnika), 2) prevencija recidiva bolesti (47%), te nestanak bolesti 
(38%), pri čemu treba napomenuti da niti u jednog bolesnika nije zabilježeno pogoršanje zdravlja. Stoga dobiveni rezul-
tati konvencionalnih onkoloških terapija u kombinaciji s adjuvantnom terapijom Isorelom ukazuju na korisnost ovakvog 
integrativnog medicinskog pristupa u 85% onkoloških bolesnika, bez neželjenih popratnih pojava.
